Assessing the clinical utility of cancer genomic and proteomic data across tumor types

Nature Biotechnology

Volumn 32, Issue 7, 2014, Pages 644-652

  Yuan, Yuan ^a,b   Van Allen, Eliezer M ^c,d   Omberg, Larsson ^e   Wagle, Nikhil ^c,d   Amin Mansour, Ali ^d   Sokolov, Artem ^f   Byers, Lauren A ^b   Xu, Yanxun ^g   Hess, Kenneth R ^b   Diao, Lixia ^b   Han, Leng ^b   Huang, Xuelin ^b   Lawrence, Michael S ^d   Weinstein, John N ^b   Stuart, Josh M ^f   Mills, Gordon B ^b   Garraway, Levi A ^c,d,h   Margolin, Adam A ^e,j   Getz, Gad ^d,h,i   Liang, Han ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e SAGE BIONETWORKS   (United States)

^f University of California Santa Cruz   (United States)

^g UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j Oregon Health and Science University Department of Biomedical Engineering   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; GENES; RNA; TUMORS;

CLINICAL MANAGEMENT; CLINICAL UTILITY; COPY-NUMBER ALTERATIONS; MODEL EVALUATION; MOLECULAR PROFILING; PATIENT SURVIVALS; PROTEIN EXPRESSIONS; THERAPEUTIC STRATEGY;

INFORMATION MANAGEMENT;

EVEROLIMUS; MESSENGER RNA; MICRORNA; MICRORNA 101; MICRORNA 143; MICRORNA 192; MICRORNA 21; MICRORNA LET 7A; MICRORNA LET 7F; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; RAPAMYCIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER GENETICS; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CLASSIFICATION ALGORITHM; COMPARATIVE STUDY; CONTROLLED STUDY; COPY NUMBER VARIATION; CYSTADENOCARCINOMA; DNA METHYLATION; DNA REPAIR; FOLLOW UP; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENOMICS; GLIOBLASTOMA; HUMAN; INDEL MUTATION; KIDNEY CARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; MULTIPLE CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; RETROSPECTIVE STUDY; RNA SEQUENCE; SOMATIC MUTATION; SURVIVAL PREDICTION; TRANSITIONAL CELL CARCINOMA; TUMOR MODEL;

DATABASES, GENETIC; DNA, NEOPLASM; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; PREVALENCE; PROTEOME; RISK ASSESSMENT; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84903940391     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2940     Document Type: Article

References (50)

1. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
2. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
3. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
4. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012).
5. Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67-73 (2013).
6. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43-49 (2013).
7. Weigel, M.T. & Dowsett, M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr. Relat. Cancer 17, R245-R262 (2010).
8. Garraway, L. Genomics-driven oncology: framework for an emerging paradigm. J. Clin. Oncol. 31, 1806-1814 (2013).
9. MacConaill, L. et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS ONE 4, e7887 (2009).
10. Berchuck, A. et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin. Cancer Res. 11, 3686-3696 (2005).
11. Douillard, J.Y. et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 7, 719-727 (2006).
12. Heng, D.Y. et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 14, 141-148 (2013).
13. Johnson, D.R. & O'Neill, B.P. Glioblastoma survival in the United States before and during the temozolomide era. J. Neurooncol. 107, 359-364 (2012).
14. Harrell, F., Lee, K. & Mark, D. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 15, 361-387 (1996).
15. Tibshirani, R. Regression shrinkage and selection via the lasso. J. R. Stat. Soc., B 58, 267-288 (1996).
16. Ishwaran, H., Kogalur, U.B., Blackstone, E.H. & Lauer, M.S. Random survival forests. Ann. Appl. Stat. 2, 841-860 (2008).
17. Brunet, J.-P., Tamayo, P., Golub, T. & Mesirov, J. Metagenes and molecular pattern discovery using matrix factorization. Proc. Natl. Acad. Sci. USA 101, 4164-4169 (2004).
18. Shih, K. et al. A microRNA survival signature (MiSS) for advanced ovarian cancer. Gynecol. Oncol. 121, 444-450 (2011).
19. Jänne, P.A. et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 14, 38-47 (2013).
20. Ohashi, K. et al. Characteristics of lung cancers harboring NRAS mutations. Clin. Cancer Res. 19, 2584-2591 (2013).
21. Falconer, J.S. et al. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 75, 2077-2082 (1995).
22. Kallakury, B.V. et al. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin. Cancer Res. 7, 3113-3119 (2001).
23. Antoon, J.W. et al. Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance. Sci. Rep. 2, 539 (2012).
24. Faragalla, H. et al. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. J. Mol. Diagn. 14, 385-392 (2012).
25. Zaman, M.S. et al. Up-regulation of microRNA-21 correlates with lower kidney cancer survival. PLoS ONE 7, e31060 (2012).
26. Khella, H. et al. miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma. Carcinogenesis 34, 2231-2239 (2013).
27. Liang, S. et al. MicroRNA let-7f inhibits tumor invasion and metastasis by targeting MYH9 in human gastric cancer. PLoS ONE 6, e18409 (2011).
28. Liu, Y., Yin, B., Zhang, C., Zhou, L. & Fan, J. Hsa-let-7a functions as a tumor suppressor in renal cell carcinoma cell lines by targeting c-myc. Biochem. Biophys. Res. Commun. 417, 371-375 (2012).
29. Ni, Y. et al. MicroRNA-143 functions as a tumor suppressor in human esophageal squamous cell carcinoma. Gene 517, 197-204 (2012).
30. Noguchi, S. et al. MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett. 307, 211-220 (2011).
31. Sakurai, T. et al. The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells. Biochem. Biophys. Res. Commun. 422, 607-614 (2012).
32. Mermel, C. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
33. Shi, L. et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat. Biotechnol. 28, 827-838 (2010).
34. Van Allen, E.M., Wagle, N. & Levy, M.A. Clinical analysis and interpretation of cancer genome data. J. Clin. Oncol. 31, 1825-1833 (2013).
35. Van Allen, E.M. et al. Whole-exome sequencing and clinical interpretation of FFPE tumor samples to guide precision cancer medicine. Nat. Med. doi:10.1038/nm.3559 (18 May 2014).
36. Wagle, N. et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2, 82-93 (2012).
37. Kim, K.B. et al. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J. Clin. Oncol. 31, 482-489 (2013).
38. Iyer, G. et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 338, 221 (2012).
39. Krueger, D.A. et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N. Engl. J. Med. 363, 1801-1811 (2010).
40. Wagle, N. et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 4, 546-553 (2014).
41. Van Allen, E.M. et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 4, 94-109 (2014).
42. Wagle, N. et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 4, 61-68 (2014).
43. Holdhoff, M. et al. Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas. J. Neurooncol. 110, 279-285 (2012).
44. Sturgeon, C. et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin. Chem. 54, e11-e79 (2008).
45. McShane, L.M., Altman, D.G. & Sauerbrei, W. Identification of clinically useful cancer prognostic factors: what are we missing? J. Natl. Cancer Inst. 97, 1023-1025 (2005).
46. McShane, L.M. & Hayes, D.F. Publication of tumor marker research results: the necessity for complete and transparent reporting. J. Clin. Oncol. 30, 4223-4232 (2012).
47. Henry, N.L. & Hayes, D.F. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist 11, 541-552 (2006).
48. Bilal, E. et al. Improving breast cancer survival analysis through competition-based multidimensional modeling. PLoS Comput. Biol. 9, e1003047 (2013).
49. Margolin, A. et al. Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer. Sci. Transl. Med. 5, 181re1 (2013).
50. Yuan, Y., Xu, Y., Xu, J., Ball, R. & Liang, H. Predicting the lethal phenotype of the knockout mouse by integrating comprehensive genomic data. Bioinformatics 28, 1246-1252 (2012).